First patient dosed in BUOY-1 study targeting MDD with or without anxious distress
Category: News
Healthinote rollout aims to improve early detection and patient self-management
Digital operating rooms and histotripsy therapy combine to improve outcomes
Vertex’s once-daily triple therapy approved for eligible patients aged six and over
Sebetralstat offers injection-free relief for patients aged 12 and over
New treatment targets BRAFV600E-mutant mCRC after prior therapy
Targeting G-quadruplexes may restore chemotherapy effectiveness
New regulations aim to simplify processes and strengthen patient safety
OVX836 shown to be safe and effective alongside seasonal Fluarix Tetra